MOLECULAR DIAGNOSTICS DRIVER
MOLECULAR DIAGNOSTICS FULL

MGP-4 is comprised of two components (click here for a general overview and here for specific details of exactly what is included) which have been developed and validated in-house (we are UKAS Accredited to ISO15189). The challenge is finding these ‘gain-of-function’ associated genetic changes, if present, and then matching them to the correct inhibitory drug, if there is one available of course.

MOLECULAR DIAGNOSTICS DRIVER

A group of anti-cancer drugs, often referred to collectively as ‘targeted therapies’, can specifically inhibit or help ‘switch off’ some of these tumour (also known as oncogenic) driver events. those involved in growth), which should normally be under tight control, becoming permanently ‘switched on’. MGP (Multi-Gene Panel)-4 essentially looks for tumour specific genetic changes that result in certain cellular processes (e.g. We offer two principal NGS based tests which broadly correspond to two main types of therapeutic approach to cancer treatment. In turn, this information gives the patient’s clinical care team a better chance of finding something that can help fight it. This allows us to examine 1000’s of potential genetic changes simultaneously, thus gaining a better understanding of what aberrant cellular processes may, or sometimes equally importantly may not, be going on within a patient’s tumour.

MOLECULAR DIAGNOSTICS FULL

What tests do we offer? Next Generation Sequencing (NGS) based analysesĪlthough we offer a full range of services in order to best fit the varied needs of customers, our core tests utilise NGS technology. The assay has been validated in-house (addition to our ISO scope is pending) for use in non-small cell lung cancer ONLY and may be requested either up front or on reflex after MGP-4(DNA). Whilst this approach has realised considerable cost savings, the overall turnaround time of two back-to-back NGS assays has always been challenging. This has been designed primarily to address the issue of fusion testing ‘on reflex’ after a DNA based NGS analysis. NEW Rapid Lung Fusions Assay: Our new rapid turnaround format assay for ALK, ROS1, RET fusions and MET exon14 skipping is now live. Kindly bear with us, and please be assured that we will be doing all that we can can to keep turnaround times to an absolute minimum. Consequently, the ongoing situation with rail strikes is unfortunately likely to result in some level of periodic service disruption. General service disruption: As a laboratory based in central London, most of our staff are heavily reliant on the rail network to travel to work. Assays currently experiencing service disruption due to supply chain issues: None

Molecular diagnostics